Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628885 | 0.81 | MAPK1 (0.41) | MAPK1DYRK1A | |
| SCHEMBL2628882 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1AAKT1BTK | |
| SCHEMBL21938395 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1AAKT1 | |
| SCHEMBL27813658 | 0.69 | PRKCI (0.48) | MAPK1DYRK1AAKT1 | |
| SCHEMBL30167002 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1A | |
| SCHEMBL24348992 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1AAKT1 | |
| SCHEMBL1473042 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1A | |
| SCHEMBL1473269 | 0.69 | DYRK1A (0.53) | MAPK1DYRK1AAKT1 | |
| SCHEMBL29691438 | 0.69 | DYRK1A (0.53) | MAPK1DYRK1AAKT1 | |
| SCHEMBL3152938 | 0.69 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9730940-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME (US) | 2017-08-15 | — | — | US | claimed |
| EP-2920171-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9938281-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9730940-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160207926-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20150353552-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC | 2015-12-10 | — | — | US | disclosed |
| EP-2920172-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2920171-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014075392-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014075393-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353552-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | MAPK1 343/4885DYRK1A 3498/4885AKT1 88/4885 |
| US-20160207926-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | MAPK1 387/4885DYRK1A 3874/4885AKT1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.